These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34001453)

  • 41. [Intraductal papillary mucinous neoplasms of the pancreas: pro surgical therapy--pro surveillance].
    Uhl W; Belyaev O; Herzog T; Mueller CA; Seelig M; Schmidt W; Hohenberger W; Ellenrieder V
    Z Gastroenterol; 2008 Nov; 46(11):1290-7. PubMed ID: 19012202
    [TBL] [Abstract][Full Text] [Related]  

  • 42. International Consensus Guidelines parameters for the prediction of malignancy in intraductal papillary mucinous neoplasm are not properly weighted and are not cumulative.
    Roch AM; Ceppa EP; DeWitt JM; Al-Haddad MA; House MG; Nakeeb A; Schmidt CM
    HPB (Oxford); 2014 Oct; 16(10):929-35. PubMed ID: 25077378
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm?
    He J; Cameron JL; Ahuja N; Makary MA; Hirose K; Choti MA; Schulick RD; Hruban RH; Pawlik TM; Wolfgang CL
    J Am Coll Surg; 2013 Apr; 216(4):657-65; discussion 665-7. PubMed ID: 23395158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes of primary surveillance for intraductal papillary mucinous neoplasm.
    Cauley CE; Waters JA; Dumas RP; Meyer JE; Al-Haddad MA; DeWitt JM; Lillemoe KD; Schmidt CM
    J Gastrointest Surg; 2012 Feb; 16(2):258-67; discussion 266. PubMed ID: 22089952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
    Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
    JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.
    Turrini O; Waters JA; Schnelldorfer T; Lillemoe KD; Yiannoutsos CT; Farnell MB; Sarr MG; Schmidt CM
    HPB (Oxford); 2010 Sep; 12(7):447-55. PubMed ID: 20815853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Surgical indication for intraductal papillary mucinous neoplasm without mural nodule ≥5 mm.
    Tsumura A; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Hayami S; Ueno M; Yanagisawa A; Yamaue H
    Surgery; 2021 Feb; 169(2):388-395. PubMed ID: 32859391
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution.
    Hwang DW; Jang JY; Lee SE; Lim CS; Lee KU; Kim SW
    Langenbecks Arch Surg; 2012 Jan; 397(1):93-102. PubMed ID: 20640860
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pylorus-preserving total pancreatectomy for an intraductal papillary-mucinous neoplasm of the pancreas.
    Inagaki M; Obara M; Kino S; Goto J; Suzuki S; Ishizaki A; Tanno S; Kohgo Y; Tokusashi Y; Miyokawa N; Kasai S
    J Hepatobiliary Pancreat Surg; 2007; 14(3):264-9. PubMed ID: 17520201
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes.
    Wasif N; Bentrem DJ; Farrell JJ; Ko CY; Hines OJ; Reber HA; Tomlinson JS
    Cancer; 2010 Jul; 116(14):3369-77. PubMed ID: 20564064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Synchronous malignant intraductal papillary mucinous neoplasms of the bile duct and pancreas requiring left hepatectomy and total pancreatectomy].
    Moon DB; Lee SG; Jung DH; Park GC; Park YH; Park HW; Kim MH; Lee SK; Yu ES; Kim JH
    Korean J Gastroenterol; 2014 Feb; 63(2):129-33. PubMed ID: 24561701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Individualized surgical treatment and prognosis of intraductal papillary mucinous neoplasms of the pancreas].
    Tian XD; Wu GD; Zhuang Y; Guo XC; Yang YM
    Zhonghua Wai Ke Za Zhi; 2013 Jul; 51(7):588-91. PubMed ID: 24256581
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Surgical outcome of intraductal papillary mucinous neoplasms of the pancreas.
    Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N
    Ann Surg Oncol; 2007 Nov; 14(11):3174-80. PubMed ID: 17694416
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Malignancy predictive factors in pancreatic intraductal papillary mucinous neoplasm].
    Adet Caldelari AC; Miquel R; Bombi JA; Ginés A; Fernández-Esparrach G; Ayuso JR; Maurel J; Feu F; Castells A; Fernández-Cruz L; Navarro S
    Med Clin (Barc); 2011 Nov; 137(14):631-6. PubMed ID: 21414642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma.
    Shimada K; Sakamoto Y; Sano T; Kosuge T; Hiraoka N
    Pancreas; 2006 Apr; 32(3):281-7. PubMed ID: 16628084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience.
    Yang AD; Melstrom LG; Bentrem DJ; Ujiki MB; Wayne JD; Strouch M; Bell RH; Rao SM; Talamonti MS
    Surgery; 2007 Oct; 142(4):529-34; discussion 534-7. PubMed ID: 17950345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
    Farnell MB
    J Gastrointest Surg; 2008 Mar; 12(3):414-6. PubMed ID: 17968632
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are preoperative blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios useful in predicting malignancy in surgically-treated mucin-producing pancreatic cystic neoplasms?
    Goh BK; Tan DM; Chan CY; Lee SY; Lee VT; Thng CH; Low AS; Tai DW; Cheow PC; Chow PK; Ooi LL; Chung AY
    J Surg Oncol; 2015 Sep; 112(4):366-71. PubMed ID: 26280242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of a nomogram to predict the risk of cancer in patients with intraductal papillary mucinous neoplasm and main duct dilatation of 10 mm or less.
    Jung W; Park T; Kim Y; Park H; Han Y; He J; Wolfgang CL; Blair A; Rashid MF; Kluger MD; Su GH; Chabot JA; Yang CY; Lou W; Valente R; Del Chiaro M; Shyr YM; Wang SE; van Huijgevoort NCM; Besselink MG; Yang Y; Kim H; Kwon W; Kim SW; Jang JY
    Br J Surg; 2019 Dec; 106(13):1829-1836. PubMed ID: 31441048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.